These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 19697195

  • 1. Intravaginal use of natural micronised progesterone to prevent pre-term birth: a randomised trial in India.
    Majhi P, Bagga R, Kalra J, Sharma M.
    J Obstet Gynaecol; 2009 Aug; 29(6):493-8. PubMed ID: 19697195
    [Abstract] [Full Text] [Related]

  • 2. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial.
    DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, Soma-Pillay P, Porter K, How H, Schakis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW.
    Ultrasound Obstet Gynecol; 2007 Oct; 30(5):697-705. PubMed ID: 17899571
    [Abstract] [Full Text] [Related]

  • 3. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
    Shambhavi S, Bagga R, Bansal P, Kalra J, Kumar P.
    J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
    [Abstract] [Full Text] [Related]

  • 4. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone.
    Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A, PREDICT Group.
    Ultrasound Obstet Gynecol; 2011 Sep; 38(3):272-80. PubMed ID: 21739497
    [Abstract] [Full Text] [Related]

  • 5. Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis.
    Klein K, Rode L, Nicolaides KH, Krampl-Bettelheim E, Tabor A, PREDICT Group.
    Ultrasound Obstet Gynecol; 2011 Sep; 38(3):281-7. PubMed ID: 21739499
    [Abstract] [Full Text] [Related]

  • 6. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial.
    Serra V, Perales A, Meseguer J, Parrilla JJ, Lara C, Bellver J, Grifol R, Alcover I, Sala M, Martínez-Escoriza JC, Pellicer A.
    BJOG; 2013 Jan; 120(1):50-7. PubMed ID: 22882759
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth.
    Glover MM, McKenna DS, Downing CM, Smith DB, Croom CS, Sonek JD.
    Am J Perinatol; 2011 May; 28(5):377-81. PubMed ID: 21380990
    [Abstract] [Full Text] [Related]

  • 8. Progesterone use after successful treatment of threatened pre-term delivery.
    Areia A, Fonseca E, Moura P.
    J Obstet Gynaecol; 2013 Oct; 33(7):678-81. PubMed ID: 24127952
    [Abstract] [Full Text] [Related]

  • 9. Vaginal progesterone after tocolytic therapy in threatened preterm labor.
    Bomba-Opon DA, Kosinska-Kaczynska K, Kosinski P, Wegrzyn P, Kaczynski B, Wielgos M.
    J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1156-9. PubMed ID: 21967664
    [Abstract] [Full Text] [Related]

  • 10. A survey of clinician and patient attitudes towards the use of progesterone for women at risk of preterm birth.
    Dodd JM, Ashwood P, Flenady V, Jenkins-Manning S, Cincotta R, Crowther CA.
    Aust N Z J Obstet Gynaecol; 2007 Apr; 47(2):106-9. PubMed ID: 17355298
    [Abstract] [Full Text] [Related]

  • 11. Association of risk factors with spontaneous preterm birth after 28 weeks and neonatal outcome--a case-control study in a tertiary care referral centre.
    Subapriya K, Rao AA.
    J Indian Med Assoc; 2009 Feb; 107(2):83-4, 86-7. PubMed ID: 19585815
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial.
    Karakus S, Kiran G, Ciralik H.
    Aust N Z J Obstet Gynaecol; 2009 Dec; 49(6):685-8. PubMed ID: 20070724
    [Abstract] [Full Text] [Related]

  • 13. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial.
    O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, Soma-Pillay P, Porter K, How H, Schackis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW.
    Ultrasound Obstet Gynecol; 2007 Oct; 30(5):687-96. PubMed ID: 17899572
    [Abstract] [Full Text] [Related]

  • 14. [Progesterone for prevention of preterm delivery: only in trial setting].
    Lim AC, Mol BW, Bruinse HW.
    Ned Tijdschr Geneeskd; 2010 Oct; 154():A1730. PubMed ID: 20858311
    [Abstract] [Full Text] [Related]

  • 15. Interconceptional antibiotics to prevent spontaneous preterm birth: a randomized clinical trial.
    Andrews WW, Goldenberg RL, Hauth JC, Cliver SP, Copper R, Conner M.
    Am J Obstet Gynecol; 2006 Mar; 194(3):617-23. PubMed ID: 16522388
    [Abstract] [Full Text] [Related]

  • 16. An economic evaluation of alternative test-intervention strategies to prevent spontaneous pre-term birth in singleton pregnancies.
    Tsourapas A, Roberts TE, Barton PM, Honest H, Forbes C, Hyde CJ, Khan KS.
    Acta Obstet Gynecol Scand; 2009 Mar; 88(12):1319-30. PubMed ID: 19943821
    [Abstract] [Full Text] [Related]

  • 17. Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor.
    Choudhary M, Suneja A, Vaid NB, Guleria K, Faridi MM.
    Int J Gynaecol Obstet; 2014 Jul; 126(1):60-3. PubMed ID: 24807871
    [Abstract] [Full Text] [Related]

  • 18. Progestational agents for the prevention of preterm birth.
    Lamont RF, Jayasooriya GS.
    J Perinat Med; 2009 Jul; 37(1):12-4. PubMed ID: 18999914
    [Abstract] [Full Text] [Related]

  • 19. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
    Hall NR.
    Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
    [Abstract] [Full Text] [Related]

  • 20. Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone.
    Maher MA, Abdelaziz A, Ellaithy M, Bazeed MF.
    Acta Obstet Gynecol Scand; 2013 Feb; 92(2):215-22. PubMed ID: 23016508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.